Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713075 | 0.90 | CXCR4 (0.50) | CARM1PRMT6CXCR4MCHR1CHRM2 | |
| SCHEMBL3770111 | 0.87 | CXCR4 (0.49) | CARM1PRMT6CXCR4MCHR1CHRM2 | |
| SCHEMBL710582 | 0.84 | CARM1 (0.45) | CARM1PRMT6CXCR4MCHR1CHRM2 | |
| SCHEMBL3777511 | 0.84 | CXCR4 (0.45) | CARM1PRMT6CXCR4MCHR1CHRM2 | |
| SCHEMBL3770856 | 0.82 | CXCR4 (0.51) | CARM1PRMT6CXCR4MCHR1CHRM2 | |
| SCHEMBL3777751 | 0.81 | CXCR4 (0.49) | CARM1PRMT6CXCR4CHRM2KDM2B | |
| SCHEMBL3776502 | 0.79 | CHRM2 (0.43) | CARM1PRMT6CXCR4CHRM2SLC6A9 | |
| SCHEMBL710943 | 0.77 | P2RX7 (0.53) | CARM1PRMT6MCHR1P2RX7KDM2B | |
| SCHEMBL5505044 | 0.77 | CXCR4 (0.43) | CARM1PRMT6CXCR4CHRM2P2RX7 | |
| SCHEMBL711118 | 0.77 | CXCR4 (0.43) | CARM1PRMT6CXCR4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | CARM1 2561/4885PRMT6 1238/4885CXCR4 815/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | CARM1 2205/4885PRMT6 1218/4885CXCR4 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.